HS
CRNX icon

HighVista Strategies’s Crinetics Pharmaceuticals CRNX Stock Holding History

HighVista Strategies’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28,911
Closed -$970K – 155
2025
Q1 		$970K Hold
28,911
– – 0.37% 114
2024
Q4 		$1.48M Hold
28,911
– – 0.55% 69
2024
Q3 		$1.48M Sell
28,911
-6,326
-18% -$326K 0.51% 82
2024
Q2 		$1.58M Buy
35,237
+19,338
+122% +$893K 0.58% 61
2024
Q1 		$744K Hold
15,899
– – 0.27% 104
2023
Q4 		$566K Buy
+15,899
New +$488K 0.21% 114
2023
Q3 		– Sell
-32,623
Closed -$588K – 144
2023
Q2 		$588K Sell
32,623
-15,622
-32% -$312K 0.27% 113
2023
Q1 		$775K Sell
48,245
-45,648
-49% -$845K 0.63% 52
2022
Q4 		$1.72M Buy
93,893
+1,846
+2% +$32.5K 1.02% 31
2022
Q3 		$1.81M Buy
92,047
+59,099
+179% +$1.21M 1.03% 31
2022
Q2 		$614K Sell
32,948
-11,278
-26% -$225K 0.37% 66
2022
Q1 		$971K Sell
44,226
-8,756
-17% -$177K 0.62% 36
2021
Q4 		$1.5M Buy
+52,982
New +$1.31M 1.2% 22
2020
Q4 		– Sell
-30,845
Closed -$483K – 120
2020
Q3 		$483K Buy
30,845
+5,144
+20% +$78.6K 0.35% 52
2020
Q2 		$450K Buy
+25,701
New +$438K 0.37% 31

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighVista Strategies's CRNX Position: Q2 2025 in Review

HighVista Strategies sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2025, closing a stake of 28,911 shares — an estimated $970K sold.

HighVista Strategies first reported a position in CRNX in Q2 2020 and held it in 15 quarters. The position peaked at $1.81M in Q3 2022. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

  • HighVista Strategies reported no remaining Crinetics Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • HighVista Strategies sold 28,911 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $970K.
  • HighVista Strategies first reported a position in Crinetics Pharmaceuticals in Q2 2020 and held it in 15 quarters.
  • HighVista Strategies's Crinetics Pharmaceuticals position peaked at $1.81M in Q3 2022.
  • 222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on HighVista Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.